REGENXBIO Announces Positive Data from Pivotal Dose Level of RGX-121 Demonstrating Long-Term…
REGENXBIO Inc. announced positive results from the Phase I/II/III CAMPSIITE trial of RGX-121 for the treatment of patients with Mucopolysaccharidosis Type II (MPS II), also known as…
Read More...
Read More...